BioPharmSignal logoBioPharmSignal

Biotech News

AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)

AngioDynamics (ANGO)AngioDynamics2026-06-25 13:46 ESTFDA / regulatory

Prospective Feasibility Study to Examine IRE as a Tissue-Sparing, Minimally Invasive Option for Men with BPH-Related Lower Urinary Tract Symptoms LATHAM, N.Y. --(BUSINESS WIRE)--Jun. 17, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow

Open original release

Related news

ANGOAngioDynamics2026-06-25 13:46 EST

AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect

ANGOAngioDynamics2026-06-25 13:46 EST

AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

ANGOAngioDynamics2026-06-25 13:46 EST

AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer

ANGOAngioDynamics2026-06-25 13:46 EST

AngioDynamics to Present at the 44th Annual J.P. Morgan Healthcare Conference

ANGOAngioDynamics2026-06-25 13:46 EST

AngioDynamics to Report Fiscal 2026 Second Quarter Results on January 6, 2026

ANGOAngioDynamics2026-06-25 13:46 EST

AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability

ANGOAngioDynamics2026-06-25 13:46 EST

AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance

ANGOAngioDynamics2026-06-25 13:46 EST

AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care

ANGOAngioDynamics2026-06-25 13:46 EST

AngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation Platform

ANGOAngioDynamics2026-06-25 13:46 EST

AngioDynamics to Present at the Leerink Partners Global Healthcare Conference

View all latest news

AngioDynamics

AngioDynamics is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

ANGOAngioDynamics2026-06-26 06:10 EST

AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)

ANGOAngioDynamics2026-06-26 06:10 EST

AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect

ANGOAngioDynamics2026-06-26 06:10 EST

AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

ANGOAngioDynamics2026-06-26 06:10 EST

AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer

ANGOAngioDynamics2026-06-26 06:10 EST

AngioDynamics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States